Welcome to our dedicated page for Sol Gel Technolg news (Ticker: SLGL), a resource for investors and traders seeking the latest updates and insights on Sol Gel Technolg stock.
Sol Gel Technologies Ltd (SLGL) is a clinical-stage pharmaceutical innovator focused on advancing topical dermatology treatments through its proprietary silica-based microencapsulation technology. This page aggregates all official company announcements, including updates on acne and rosacea therapies in development.
Investors and industry professionals will find timely updates on regulatory milestones, clinical trial progress, and strategic partnerships. The curated news collection provides insights into SLGL's pipeline advancements and commercialization efforts for its controlled-release drug delivery platform.
Key updates include earnings reports, FDA correspondence, licensing agreements, and research breakthroughs. All content is sourced directly from company filings and verified press releases to ensure accuracy.
Bookmark this page for streamlined access to SLGL's latest developments in dermatological innovation. Check regularly for authoritative updates on this clinical-stage leader's progress in enhancing topical treatment efficacy and safety.
Sol-Gel Technologies announced on May 28, 2024, receiving a notification from Nasdaq regarding non-compliance with the minimum bid price rule of $1 per share. The company’s shares have traded below $1 for 33 consecutive business days, triggering this notice. This notice does not affect the current listing, and shares will continue trading under the symbol SLGL. Sol-Gel has 180 days, until November 18, 2024, to regain compliance. If the share price reaches $1 for 10 consecutive days before the deadline, compliance will be restored. Sol-Gel is evaluating options to address this issue.
Sol-Gel Technologies (NASDAQ: SLGL) announced its Q1 2024 financial results and corporate updates. Key highlights include an ongoing Phase 3 trial of SGT-610 for Gorlin Syndrome and a proof-of-concept study for SGT-210 in Darier disease. The company entered an Asset Purchase Agreement with Beimei Pharma to commercialize TWYNEO® in several regions, potentially earning up to $15M. Financially, Q1 revenue was $0.5M, up from $0.3M in Q1 2023. However, total prescriptions for TWYNEO and EPSOLAY declined by 23% and 14% respectively. R&D expenses decreased to $5.3M, contributing to a reduced net loss of $6.3M compared to $10.7M in Q1 2023.
Sol-Gel Technologies (NASDAQ: SLGL) has entered into a significant asset purchase agreement with Shenzhen Beimei Pharmaceutical Co. to commercialize TWYNEO® for acne vulgaris in mainland China, Hong Kong, Macau, Taiwan, and Israel.
Sol-Gel will receive up to $15 million, including $10 million in upfront and regulatory milestone payments, with the remaining $5 million as royalties on net sales. This agreement enhances the potential reach of TWYNEO beyond the U.S. market.
Beimei will handle the registration and commercialization of TWYNEO in these regions. This strategic move aims to address the unmet clinical need in the acne market, particularly among adolescents in China.
FAQ
What is the current stock price of Sol Gel Technolg (SLGL)?
What is the market cap of Sol Gel Technolg (SLGL)?
